{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-179466","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.878559+00:00","generated_at":"2026-05-17T13:57:56.774030+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Kalaris Therapeutics stockholders elect two Class II directors, ratify Deloitte as auditor","bullets":["Srinivas Akkaraju and Andrew Oxtoby elected as Class II directors for three-year terms expiring 2028.","Akkaraju: 14,626,646 for, 144,695 withheld; Oxtoby: 14,668,424 for, 102,917 withheld.","Ratification of Deloitte & Touche as independent auditor for FY2025 approved with 16,090,928 for, 6,975 against, 1,786 abstain.","Broker non-votes of 1,328,348 on director elections due to routine matters."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-179466","json":"https://secwatch.observer/filing/0001193125-25-179466.json","markdown":"https://secwatch.observer/filing/0001193125-25-179466.md","text":"https://secwatch.observer/filing/0001193125-25-179466.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/0001193125-25-179466-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312525179466/d885835d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:57:56.774030+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}